Pfizer (NYSE:PFE) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of Pfizer (NYSE:PFE) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports.

A number of other analysts also recently issued reports on the stock. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.73 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business’s 50 day moving average price is $26.28 and its 200 day moving average price is $27.18. The company has a market cap of $145.79 billion, a price-to-earnings ratio of 18.24, a PEG ratio of 0.64 and a beta of 0.61. Pfizer has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 EPS. The company’s revenue was up 24.7% compared to the same quarter last year. On average, research analysts predict that Pfizer will post 2.95 EPS for the current year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC lifted its position in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.